Does "clock" matter in prostate cancer?

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 1, 2006, Pages 3-5

  Zhu, Yong ^a   Zheng, Tongzhang ^a   Stevens, Richard G ^b   Zhang, Yawei ^a   Boyle, Peter ^c  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CYCLIN D1; DNA;

APOPTOSIS; CANCER GENETICS; CANCER RESEARCH; CANCER RISK; CARCINOGENESIS; CIRCADIAN RHYTHM; DNA DAMAGE; EPIGENETICS; GENE EXPRESSION REGULATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LIGHT EXPOSURE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; ARTICLE; BIOLOGICAL RHYTHM; GENETICS; MALE; METABOLISM; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY; PROSTATE TUMOR;

ANDROGENS; BIOLOGICAL CLOCKS; CIRCADIAN RHYTHM; HUMANS; MALE; PHENOTYPE; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS;

EID: 33645454602     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0631     Document Type: Review

References (33)

1. Zhu Y, Brown HN, Zhang Y, Stevens RG, Zheng T. Period3 structural variation: a circadian biomarker associated with breast cancer in young women. Cancer Epidemiol Biomarkers Prev 2005;14:268-70.
2. Stevens RG, Rea MS. Light in the built environment: potential role of circadian disruption in endocrine disruption and breast cancer. Cancer Causes and Control 2001;12:279-87.
3. Fu L, Lee CC. The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer 2003;3:350-61.
4. Pukkala E, Aspholm R, Auvinen A, et al. Cancer incidence among 10,211 airline pilots: a Nordic study. Aviat Space Environ Med 2003;74:699-706.
5. Band PR, Le ND, Fang R, et al. Cohort study of Air Canada pilots: mortality, cancer incidence, and leukemia risk. Am J Epidemiol 1996;143:137-43.
6. Rafnsson V, Tulinius H, Jonasson JG, Hrafnkelsson J. Risk of breast cancer in female flight attendants: a population-based study (Iceland). Cancer Causes Control 2001;12:95-101.
7. Stevens RG. Circadian disruption and breast cancer: from melatonin to clock genes. Epidemiology 2005;16:254-8.
8. Blask DE, Dauchy RT, Sauer LA, Krause JA, Brainard GC. Growth and fatty acid metabolism of human breast cancer (MCF-7) xenografts in nude rats: impact of constant light-induced nocturnal melatonin suppression. Breast Cancer Res Treat 2003;79:313-20.
9. Bartsch C, Bartsch H, Schmidt A, Ilg S, Bichler KH, Fluchter SH. Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients: evidence for reduced pineal activity and relevance of urinary determinations. Clin Chim Acta 1992;209:153-67.
10. Zisapel N. Benign and tumor prostate cells as melatonin target sites. The pineal gland and cancer: neuroimmunoendocrine mechanisms in malignancy. Berlin: Springer; 2001.
11. Lockley SW, Skene DJ, Arendt J, Tabandeh H, Bird AC, Defrance R. Relationship between melatonin rhythms and visual loss in the blind. J Clin Endocrinol Metab 1997;82:3763-70.
12. Feychting M, Osterlund B, Ahlbom A. Reduced cancer incidence among the blind. Epidemiology 1998;9:490-4.
13. Pukkala E, Ojamo M, Rudanko SL, Stevens RG, Verkasalo PK. Does incidence of breast cancer and prostate cancer decrease with increasing degree of visual impairment. Cancer Causes Control. In press.
14. Verkasalo PK, Pukkala E, Stevens RG, Ojamo M, Rudanko SL. Inverse association between breast cancer incidence and degree of visual impairment in Finland. Br J Cancer 1999;80:1459-60.
15. Hahn RA. Profound bilateral blindness and the incidence of breast cancer. Epidemiology 1991;2:208-10.
16. Stevens RG, Davis S, Thomas DB, Anderson LE, Wilson BW. Electric power, pineal function, and the risk of breast cancer. FASEB J 1992;6:853-60.
17. Young MW, Kay SA. Time zones: a comparative genetics of circadian clocks. Nat Rev Genet 2001;2:702-15.
18. Storch KF, Lipan O, Leykin I, et al. Extensive and divergent circadian gene expression in liver and heart. Nature 2002;417:78-83.
19. Bjarnason GA, Jordan RC, Sothern RB. Circadian variation in the expression of cell-cycle proteins in human oral epithelium. Am J Pathol 1999;154:613-22.
20. Morin PJ. β-Catenin signaling and cancer. BioEssays 1999;21:1021-30.
21. Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 2002;111:41-50.
22. Filipski E, King VM, Li X, et al. Host circadian clock as a control point in tumor progression. J Natl Cancer Inst 2002;94:690-7.
23. Katzenberg D, Young T, Finn L, et al. A CLOCK polymorphism associated with human diurnal preference. Sleep 1998;21:569-76.
24. Ebisawa T, Uchiyama M, Kajimura N, et al. Association of structural polymorphisms in the human periods gene with delayed sleep phase syndrome. EMBO Rep 2001;2:342-6.
25. Archer SN, Robilliard DL, Skene DJ, et al. A length polymorphism in the circadian clock gene Per3 is linked to delayed sleep phase syndrome and extreme diurnal preference. Sleep 2003;26:413-5.
26. Brown CE, Warren S, Chute RN, Ryan KJ, Todd RB. Hormonally induced tumors of the reproductive system of parabiosed male rats. Cancer Res 1979;39:3971-6.
27. Gann PH, Hennekens CH, Ma J, Longcope C, Stampfer MJ. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996;88:1118-26.
28. Soronen P, Laiti M, Torn S, et al. Sex steroid hormone metabolism and prostate cancer. J Steroid Biochem Mol Biol 2004;92:281-6.
29. Francavilla A, Eagon PK, DiLeo A, et al. Circadian rhythm of hepatic cytosolic and nuclear estrogen and androgen receptors. Gastroenterology 1986;91:182-8.
30. Plymate SR, Tenover JS, Bremner WJ. Circadian variation in testosterone, sex hormone-binding globulin, and calculated non-sex hormone-binding globulin bound testosterone in healthy young and elderly men. J Androl 1989;10:366-71.
31. Guignard MM, Pesquies PC, Serrurier BD, Merino DB, Reinberg AE. Circadian rhythms in plasma levels of cortisol, dehydroepiandrosterone, δ4-androstenedione, testosterone and dihydrotestosterone of healthy young men. Acta Endocrinol 1980;94:536-45.
32. Lee CC. The circadian clock and tumor suppression by Mammalian period genes. Methods Enzymol 2005;393:852-61.
33. Lim JT, Mansukhani M, Weinstein IB. Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells. Proc Natl Acad Sci U S A 2005;102:5156-61.